Stock Market & Financial Investment News

News Breaks January 22, 2013 13:40 EDT MDVN, JNJ J&J results imply strength for Medivation drug, says William Blair William Blair believes Johnson & Johnson's (JNJ) Q4 results this morning, which included the trending down of sales for its metastatic prostate cancer drug Zytiga, implies strength for Medivation's (MDVN) Xtandi. The firm believes J&J's decreased sales of Zytiga in Q4 were largely due to competitor Xtandi's U.S. launch in September. William Blair keeps an Outperform rating on shares of Medivation, which are trading up 4% to $57.10 after J&J's results. News For MDVN;JNJ From The Last 14 Days Check below for free stories on MDVN;JNJ the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 21, 2013 07:24 EDT JNJ Global Health Care to host a conference Subscribe for More Information May 17, 2013 06:19 EDT JNJ J&J to end sales of of metal-on-metal hip replacements, Bloomberg reports Subscribe for More Information May 15, 2013 16:51 EDT JNJ FDA approves Simponi to treat ulcerative colitis Subscribe for More Information May 14, 2013 14:59 EDT MDVN Medivation has a conference call hosted by JPMorgan JPMorgan Analysts Meacham and Kasimov host a conference call with CEO David Hung on May 16 at 10 am. May 10, 2013 11:48 EDT JNJ Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 06:16 EDT JNJ Obesity surgery booming in India, Bloomberg reports Subscribe for More Information May 9, 2013 17:09 EDT JNJ Johnson & Johnson deal to settle sales practices probe stalls, WSJ reports Johnson & Johnson's $2.2B settlement with the Justice Department related to its promotion of certain drugs is on hold as the company is looking to avoid language in the agreement that could make it vulnerable to private lawsuits, reports The Wall Street Journal, citing people familiar with the talks. Reference Link 16:23 EDT MDVN Medivation sees FY13 operating expenses, net of Astellas payments, $285M-$300M Subscribe for More Information 16:23 EDT MDVN Medivation reports Q1 EPS (36c), consensus (41c) Reports Q1 revenue $46.15M, consensus $38.54M. 15:27 EDT MDVN Notable companies reporting after market close Notable companies reporting after the market close, with earnings consensus, include priceline.com (PCLN), consensus $5.27; Public Storage (PSA), consensus $1.62; NVIDIA (NVDA), consensus 10c; CareFusion (CFN), consensus 53c; Assured Guaranty (AGO), consensus 68c; Medivation (MDVN), consensus (41c); Great Plains Energy (GXP), consensus 12c; Salix Pharmaceuticals (SLXP), consensus 68c; Air Lease (AL), consensus 38c; Sotheby's (BID), consensus (12c). 09:51 EDT JNJ J&J unit says first patient enrolled in reMARQable study Subscribe for More Information May 8, 2013 07:38 EDT JNJ BofA/Merrill's medical tech analyst hold an analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.